Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
How much higher do we need to go before the bears believe this rally is real?
The Lightning Round is extended in this CNBC.com exclusive feature.
I'm happy to report that I'm scribbling out this blog from the air-conditioned comfort of the convention center in Orlando. It's the first time in my six or seven years of covering ASCO that the organization has let CNBC broadcast live from inside. And, guess what? No one seems freaked out about it.
Sliding home prices, more trouble in the Eurozone and another North Korean nuclear bomb test: How will these affect the stock markets? Art Cashin, UBS Financial Services director of floor operations, offered CNBC his insights on Tuesday.
Wall Street looks ready to transfer funds from bullish to bearish names, the Mad Money host says.
Stocks lost more than 2% Wednesday as bank shares continued to struggle and retail sales unexpectedly fell for a second straight month.
A gloomy sales report dragged down investor sentiment on Wednesday sending the S&P 500 to its third straight day of declines.
Stocks declined Wednesday as bank shares continued to struggle and retail sales unexpectedly fell for a second straight month. A brief reprieve after the business-inventories report and comments from President Obama fizzled.
What does it say when a drugmaker hires a Goldman Sachs investment banker as its next Chief Financial Officer? That's the question I'm asking after Novartis announced that it's tapped a managing director of investment banking at Goldman Sachs, Jonathan Symonds, as its CFO apprentice.
Stocks pared their losses Wednesday after a report showed business inventories shrunk at a slower pace and remarks from President Obama on health-care reform. Still, stocks remained under pressure as bank shares continued to struggle and retail sales unexpectedly fell for a second straight month.
With stocks rallying for over 2 months now, dividend yields continue to fall back to Earth. The average dividend yield of the Dow 30 has fallen nearly 30% since the rally began in early March. See how the 30 companies in the Dow compare.
Comments made by Intel CEO Paul Otellini after hours could be bullish for stocks.
Stocks lost ground in afternoon trading but traded in a fairly tight range, though the Nasdaq posted losses approaching 1.5 percent.
Stocks opened slightly higher, bouncing off a rough day Monday but moving hesitantly as an economic report showed consumer weakness continues to hamper growth.
The Glaxo announcement contained the results of the first head-to-head study of GSK’s Cervarix versus Merck’s Gardasil. They’re the shots for the sexually transmitted virus that can cause genital warts and cervical cancer. MRK’s is already on the market. GSK’s has been delayed in getting there.
A new study shows that Merck's Gardasil vaccine protects some young women from a strain of a sexually transmitted disease that can lead to cervical cancer for nearly a decade.
In this Web Extra, we bring you the day's biggest winners and losers. Find out why shares of Philip Morris and Merck popped while AT&T and Micron dropped.
Don't get so swept up in trying to predict where specific stocks are going that you ignore what they're saying about the market as a whole.
Forget politics. Cramer has a better way to judge the president's performance: stocks.